Hudson Bay Capital Management
CRBP icon

Hudson Bay Capital Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Hudson Bay Capital Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,578
Closed -$278K – 1415
2026
Q1 		$278K Buy
29,578
+12,489
+73% +$105K ﹤0.01% 1048
2025
Q4 		$139K Buy
+17,089
New +$211K ﹤0.01% 995
2024
Q3 		– Sell
-43,000
Closed -$1.95M – 907
2024
Q2 		$1.95M Hold
43,000
– – 0.01% 530
2024
Q1 		$1.69M Buy
+43,000
New +$1.06M 0.01% 483

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Hudson Bay Capital Management's CRBP Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 29,578 shares — an estimated $278K sold.

Hudson Bay Capital Management first reported a position in CRBP in Q1 2024 and held it in 4 quarters. The position peaked at $1.95M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 29,578 Corbus Pharmaceuticals shares in Q2 2026, an estimated $278K.
  • Hudson Bay Capital Management first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Hudson Bay Capital Management's Corbus Pharmaceuticals position peaked at $1.95M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.